Intravitreal sunitinib maleate- GrayBug Vision

Drug Profile

Intravitreal sunitinib maleate- GrayBug Vision

Alternative Names: GB 102- GrayBug Vision; GB 103- GrayBug Vision

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GrayBug inc.
  • Class Amides; Antineoplastics; Ethylamines; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Colony stimulating factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Age-related macular degeneration
  • Preclinical Diabetic macular oedema; Retinal vein occlusion

Most Recent Events

  • 06 Oct 2017 Chemical structure information added
  • 14 Sep 2017 Preclinical trials in Diabetic macular oedema in USA (Intravitreous)
  • 14 Sep 2017 Preclinical trials in Retinal vein occlusion in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top